ASCO em contexto

Evento 100% Online - Inscrições Gratuitas

DATA: 27 de junho de 2020

Apresentação: O Congresso Anual da Sociedade Americana de Oncologia Clínica (ASCO), traz inúmeras novidades, com impacto direto na prática da oncologia. O objetivo desse evento é discutir os principais resultados apresentados em cada área, e trazê-los para o dia-a-dia do cuidado oncológico.

Público-alvo: oncologistas clínicos, cirurgiões, radio-oncologistas, médicos residentes


Programação: 27 de junho de 2020 (sábado)

Programação sujeita a alterações e confirmações de convidados

08h00 – 08h10


Artur Katz

Temática: Mama

Coordenador: Artur Katz


Trabalhos selecionados – Parte 1

Marina Sahade

  1. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
  2. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.
  3. Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
  4. Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).


Trabalhos selecionados – Parte 2

Marcelo Cruz

  1. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
  2. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)
  3. PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
  4. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).


Resultados em perspectiva

Romualdo Barroso


Discussão e Q&A – Mama

Max Mano

Temática: Neuro

Coordenador: Olavo Feher


Trabalhos selecionados

Rodrigo Medeiros

  1. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).
  2. Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.
  3. Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
  4. Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas.


Resultados em perspectiva

Caroline Chaul


Discussão e Q&A – Neuro

Olavo Feher



Temática: Tumores GU

Coordenador: Diogo Bastos


Trabalhos selecionados – Câncer de Próstata

David Queiroz

  1. Therap trial
  2. HERO trial
  3. Estudo LACOG0415
  4. Atualização de sobrevida de M0 CRPC


Trabalhos selecionados – Câncer renal e urotelial

Fernando Vidigal

  1. JAVELIN 100 Bladder trial
  2. IMvigor 010 study
  3. IMvigor 130 biomarker study
  4. Keynote 426 update


Resultados em perspectiva

Igor Morbeck


Discussão e Q&A – GU

Denis Jardim


Intervalo para almoço

Temática: Tumores GI

Coordenador: Jorge Sabbaga


Trabalhos selecionados – Tumores colorretais

Fernanda Capareli

  1. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study.
  2. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.
  3. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
  4. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study.


Trabalhos selecionados – Tumores não colorretais

Tulio Pfiffer

  1. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01)
  2. Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
  3. ESPAC-5F: Four arm, prospective, multicenter, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
  4. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).


Resultados em perspectiva

Gustavo Fernandes


Discussão e Q&A – GI

Frederico Costa

Temática: Pulmão e cabeça/pescoço

Coordenador: Gilberto Castro


Trabalhos selecionados – Cabeça e pescoço

Ciro de Souza

  1. Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).
  2. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
  3. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).
  4. Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.
  5. Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection in operable T1-T2N0 oral and oropharyngeal cancer.


Trabalhos selecionados – Pulmão

Andrea Shimada

  1. Osimertinib as adjuvante therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
  2. KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
  3. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vc 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
  4. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
  5. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
  6. Efficacy safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).


Resultados em perspectiva

Fernando Santini



Rodrigo Medeiros



Temática: Melanoma/Sarcoma

Coordenador: Rodrigo Munhoz


Trabalhos selecionados – Parte 1

Allan Pereira

  1. A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.
  2. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. + Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
  3. Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
  4. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).


Trabalhos selecionados – Parte 2

Luiza Dib

  1. Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.
  2. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
  3. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma + Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.
  4. Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.


Resultados em perspectiva

Rodrigo Munhoz


Discussão e Q&A – Melanoma/Sarcoma

Marina Sahade

Temática: Tumores ginecológicos

Coordenadora: Daniele Assad


Trabalhos selecionados – Parte 1

Mariana Scaranti

  1. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
  2. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
  3. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
  4. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.


Trabalhos selecionados – Parte 2

Rudinei Linck

  1. Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.
  2. Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.
  3. Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy: Final outcomes of TROPHIMMUN phase II trial, cohort A.
  4. A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.


Resultados em perspectiva

Daniela Freitas


Discussão e Q&A – Tumores ginecológicos

Karime Kalil


Encerramento das atividades

Informações Gerais

Informações e Inscrições

Telefone: 11 3394-0100


Serviço de manobrista – Pago no local
Rua Professor Daher Cutait, 69 – Bela Vista.


Disponível no final do curso com carga horária.

Todos os Cursos

Inscreva-se em Nossos Cursos

Inscrição em Cursos